Nanobiotix Raises $100M After Full Exercise of Over-Allotment Option

Event summary

  • Nanobiotix's underwriters fully exercised their over-allotment option, raising gross proceeds to approximately $100 million.
  • The offering included 2,218,467 ordinary shares and 345,099 pre-funded warrants, priced at $38.98 per ADS.
  • Proceeds will be allocated: <10% to JNJ-1900 (NBTXR3) development, 50-60% to Nanoprimer and other platforms, and 30-40% for general corporate purposes.
  • The company expects the funds to support operations into 2029 based on current cash burn rate.

The big picture

Nanobiotix's successful $100 million raise underscores investor confidence in its physics-based cancer treatment platforms. The funding comes at a critical juncture as the company advances its Nanoprimer technology and other pipelines, positioning itself in a crowded oncology market. The strategic allocation of proceeds will be key to sustaining its competitive edge and operational runway through 2029.

What we're watching

Execution Risk
Whether Nanobiotix can deliver on its development plans with the raised capital, given the variability in clinical trial timelines and outcomes.
Strategic Allocation
How the company allocates the proceeds between its Nanoprimer platform and other initiatives, which could impact its long-term competitive positioning.
Market Dynamics
The pace at which Nanobiotix can translate its physics-based therapeutic approaches into commercial success, especially in the competitive oncology space.